Legal & Services

Organization Investment Process Risk Management Contact Team Bellevue Asset Management is an authorized asset manager of collective investment schemes subject to regulation by the Swiss Financial Market Supervisory Authority FINMA. As such, it is in compliance with all regulatory and legal requirements placed upon managers of collective investment schemes. Bellevue Asset Management is responsible for the operating activities of BB Biotech AG and for the investment management operations of the Bellevue Funds (Lux) SICAV and other investment funds and mandates.

FINMA authorisation

Luxembourg investment funds

Bellevue Funds

RBC, Luxembourg, is responsible for fund administration, custodian services and order processing for our Luxembourg-based investment funds. We work with the following local partners in the markets where Bellevue funds are authorized for public distribution: 

Representative in Switzerland

Acolin Fund Services AG
Affolternstrasse 56
CH-8050 Zürich

Paying agent in Switzerland

Bank am Bellevue AG
Seestrasse 16
CH-8700 Küsnacht 

Main sales office

Bellevue Asset Management AG
Seestrasse 16
CH-8700 Küsnacht/Zürich 

Paying agent, information and distribution centre in Germany

Bank Julius Bär (Europe) AG
An der Welle 1
Postfach 150252
D-60062 Frankfurt am Main

Paying agent, tax representative and information centre in Austria 

ERSTE BANK der oesterreichischen Sparkassen AG
Graben 21
A-1010 Wien

StarCapital Funds

DZ Privatbank S.A., is responsible for fund administration, custodian services and order processing for the StarCapital Luxembourg-based investment funds. We work with the following local partners : 

Representative and paying agent in Germany

DZ BANK AG 
Deutsche Zentral-Genossenschaftsbank 
Frankfurt am Main Platz der Republik
D-60265 Frankfurt am Main

 

Representative in Germany

StarCapital AG
Kronberger Straße 45
D-61440 Oberursel

Representative and paying agent in Austria

ERSTE BANK DER OESTERREICHISCHEN SPARKASSEN AG
Am Belvedere 1
1100 Wien

Representative in Switzerland

IP Concept (Schweiz) AG
In Gassen 6, PO Box
CH-8022 Zurich

Paying agent in Switzerland

DZ Privatbank (Schweiz) AG
Münsterhof 12, PO Box, 
CH- 8022 Zurich 

Purchase & Redemption

Our Luxembourg investment funds are traded on a daily basis. You can invest in Bellevue funds through your house bank or broker by giving the corresponding securities identification number (security number or ISIN) with your order.

Our funds are traded without any mark-up to Net Asset Value (NAV). Bellevue Asset Management does not charge a special commission on the purchase or redemption of fund units. A transaction fee might be charged by your house bank or broker.

We attach great importance to transparency and provide our clients with prompt, comprehensive information. Information on the prices of our funds can be found in the following newspapers published in Switzerland, Germany and Austria and on the following financial portals: 

Here institutional investors and financial intermediaries will find detailed information on administrative procedures and contact details in connection with the purchase and sale of fund units

ReportPDF
Change of settlement cyclePDF
Overview securities numbersPDF
UK Investor reportPDF
Overview securities numbers UKPDF
Information from 25.10.2011PDF
Bylaws PDF
Information from April 7, 2015PDF
Information from April 17,2015PDF
Information from May 6,2015PDF
Contact personsPDF
Payment instructionsPDF

 

 

Swiss Investment Fund

Fund Management Company BB Entrepreneur Switzerland

PMG Fonds Management AG
Sihlstrasse 95
8001 Zürich 

BB Adamant Funds

Swisscanto Fondsleitung AG
Bahnhofstrasse 9
8001 Zürich 

Custodian BB Entrepreneur Switzerland

RBC Investor Services Bank S.A.
Esch-sur-Alzette
Zweigniederlassung Zürich
Badenerstrasse 567
Postfach 101
CH-8066 Zürich

BB Adamant Funds

Zürcher Kantonalbank
Geschäftshaus Hard A
Postfach
8010 Zürich 

We offer investment funds under Swiss law that are traded daily. You can invest in the funds at any time through your house bank or broker by giving the corresponding securities identification number (security number or ISIN) with your order.

The funds are traded without any mark-up to Net Asset Value (NAV). Bellevue Asset Management does not charge a special commission on the purchase or redemption of fund units. A transaction fee might be charged by your house bank or broker..

We attach great importance to transparency and provide our clients with prompt, comprehensive information. Information on fund prices can be found in the following daily and financial newspapers in Switzerland and on the following financial portals: 

  • NZZ
  • Finanz & Wirtschaft
  • www.fundinfo.com
  • www.zkb.ch Bloomberg
  • Reuters
  • Telekurs 

Here institutional investors and financial intermediaries will find detailed information on administrative procedures and contact persons in connection with the purchase and sale of fund units: 

ReportPDF
Identification numbersPDF
Contact personsPDF

 

 

Investment Company

BB Biotech AG is a corporation listed on the SIX Swiss Exchange, in Germany (Prime Standard) and the "Segmento Star" in Italy and is domiciled in Schaffhausen, Schwertstrasse 6. Its business purpose is to invest in biotechnology companies. Asset management, administration and marketing responsibilities have been entrusted to Bellevue Group since the company was founded. T

he Board of Directors of BB Biotech AG consists of highly reputable and experienced industry professionals and scientists: 

  • Dr. Erich Hunziker, Chairman of the Board of Directors
  • Dr. Clive Meanwell, Member of the Board of Directors
  • Prof. Dr. Dr. Klaus Strein, Member of the Board of Directors

For more information on BB Biotech please visit our website www.bbbiotech.com

Private Equity

The venture capital products were established under Guernsey law. Please contact us for information.

Bellevue Asset Management AG
Seestrasse 16 / Postfach
CH-8700 Küsnacht
Tel. +41 (0)44 267 67 00
Fax +41 (0)44 267 67 01
info(at)bellevue.ch  

Tax information

Fund nameLegal formRegulatory statusEU Savings TaxDE Investmentsteuergesetz (InvStG)AT Investmentfondsgesetz (InvFG)
BB African OpportunitiesSICAVUCITSOut of scopeTransparentKESt-Meldefonds
BB Adamant BiotechSICAVUCITSOut of scopeTransparentKESt-Meldefonds
BB Entrepreneur EuropeSICAVUCITSOut of scopeTransparentKESt-Meldefonds
BB Entrepreneur Europe SmallSICAVUCITSOut of scopeTransparentKESt-Meldefonds
BB Entrepreneur SwitzerlandSwiss FundOut of scope-
BB Adamant Global GenericsSICAVUCITSOut of scopeTransparentKESt-Meldefonds
BB Global MacroSICAVUCITSIn scopeTransparentKESt-Meldefonds
BB Adamant Global BiotechSwiss Fund
BB Adamant Global GenerikaSwiss Fund
BB Adamant Global Medtech & ServicesSwiss Fund
BB Adamant Global Healthcare Index Swiss Fund
BB Adamant MedtechSICAVUCITSOut of scopeTransparentKESt-Meldefonds
Lacuna-Adamant Asia Pacific HealthSICAVUCITSOut of scopeTransparentKESt-Meldefonds
Lacuna-Adamant Global HealthcareSICAVUCITSOut of scopeTransparentKESt-Meldefonds

 

Information about the registration in the respective countries can be found in the current Prospectus.